Publications
Search our publications, laboratory reports, meeting statements, scheduling submissions and scheduling decisions.
Can't find what you’re looking for? You can also:
- search our Resources
- use the site search bar in the top right of this screen for more results.
Use the filters below to narrow your search.
Filter results
You can narrow down the results using the filters.
Topic
- Scheduling (national classification system) (56)
- Committees and advisory bodies (45)
- Safety monitoring and information (12)
- Advertising (9)
- Manufacturing (9)
- Sunscreens (5)
- Compliance and enforcement (4)
- Fees and payments (4)
- Shortages and supply disruptions (4)
- Clinical trials (3)
- Legislation (3)
- Medicinal cannabis hub (3)
- Import and export (2)
- Breast implant hub (1)
- Cosmetics (1)
- Labelling and packaging (1)
- Metal-on-metal hip replacement implants hub (1)
- Prescription opioids hub (1)
- Unique Device Identification (UDI) hub (1)
Search
247 result(s) found, displaying 126 to 150
-
Scheduling submissionsPublic submissions on matters referred to the March 2020 scheduling meetings, and received during the interim consultation period - melatonin
-
Corporate reportsThe TGA 2019-20 Annual Performance Statistics Report has now been published.
-
Corporate reportsThis Regulation Impact Statement (RIS) is intended to assist the Australian Government in reaching a decision to address the issues relating to the safe use of sports supplements in Australia.
-
Scheduling submissionsPublic submissions on scheduling matters referred to the Joint ACMS-ACCS #25 meetings held in June 2020 - Nicotine
-
Scheduling submissionsPublic submissions made in response to the proposed amendments to the Poisons Standard referred to the ACMS #31 and Joint ACMS-ACCS #25 meetings held in June 2020
-
Corporate reportsOverview of therapeutic goods advertising complaints handling and compliance for 2019-20
-
Scheduling submissionsPublic submissions on matters referred to the March 2020 scheduling meetings, and received during the interim consultation period
-
Corporate reportsFinal Report on the impact of advertising reforms from the Expert Panel Review of Medicines and Medical Devices Regulation, and other initiatives
-
Corporate reportsThe independent review is complete and the report now published.
-
Corporate reportsGuidance for reducing assessment fees for ARTG application audits and TGA conformity assessments of medical devices (including IVDs).
-
Corporate reportsA rapid literature review of safety and performance issues.
-
Corporate reportsThe report card shows the progress made by the TGA in the 3 strategies that make up the Action Plan for Medical Devices.
-
-
Scheduling submissionsPublic submissions on matters referred to the November 2019 scheduling meetings, and received during the interim consultation period
-
Corporate reportsStatistical information for 1 July to 31 December 2019 in relation to our regulation of therapeutic goods
-
Corporate reportsIn 2019, the TGA conducted 10 pharmacovigilance inspections of Australian medicine sponsors
-
Corporate reportsThis report describes the first 12 months of the mandatory reporting scheme
-
Corporate reportsThe TGA thanks respondents who provided a submission in response to the public consultation paper.
-
Corporate reportsThe Health Products Regulation Group has published a new regulatory science strategy
-
Corporate reportsOur plan for how HPRG will maintain and build its regulatory science capability over the next 5 years
-
Corporate reportsThe TGA has finalised the outcomes of the Lower Risk Registered OTC Products Review Pilot Project
-
Corporate reportsTGA instructions for disinfectant testing.
-
Corporate reportsTargets have been met for most measures under the six KPIs
-
Corporate reportsRegulatory Impact Self-Assessment Report
-
Corporate reportsThe TGA has conducted a safety review on coumarin in topical listed medicines